Posted by Michael Wonder on 12 Apr 2022
US FDA grants fast track designation for Paradigm’s Phase 3 osteoarthritis program
12 April 2022 - Paradigm Biopharmaceuticals is pleased to announce that the U.S. FDA has granted fast track designation for the company’s Phase 3 program investigating pentosan polysulphate sodium for the treatment of osteoarthritis.
Paradigm's submission to the FDA for fast track designation needed to demonstrate the potential of Zilosul to address an unmet medical need.
